临床试验/CTRI/2018/05/013620

CTRI/2018/05/013620招募中未知

A PROSPECTIVE STUDY COMPARING OUTCOMES AND QUALITY OF LIFE AFTER LAPAROSCOPIC DONOR NEPHRECTOMY VERSUS OPEN DONOR NEPHRECTOMY

All India Institute of Medical Sciences0 个研究点目标入组 60 人开始时间: 待定最近更新: 2021年11月24日

试验速览

阶段: 未知
状态: 招募中
发起方: All India Institute of Medical Sciences
入组人数: 60

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Observational

入排标准

入选标准

•All patients undergoing donor nephrectomy who fulfill the standard donor criteria and give

排除标准

•1. Donors of recipients undergoing redo renal transplant
•2. Right donor nephrectomy

研究者

发起方

All India Institute of Medical Sciences

相似试验

Study Comparing Neurocognitive Functions In High Grade Glioma Receiving Radiation post operatively by treatment according to 2 different tumour delineation techniques

CTRI/2021/09/036822AIIMS

A study to Compare Quality of Life and side effects in patients undergoing Medical versus Surgical Castration in Metastatic Prostate cancer at Tata Memorial Hospital.

CTRI/2020/03/024111Tata Memorial Centre

进行中（未招募）

A randomised, cross-over study to compare quality of life and satisfaction in primary immunodeficient patients treated with subcutaneous injections of Gammanorm® 165 mg/mL administered with two different delivery devices: injections using an infusion pump or syringeimmunodeficiency syndromeMedDRA version: 19.0Level: HLTClassification code 10036700Term: Primary immunodeficiency syndromesSystem Organ Class: 100000004870

EUCTR2014-003746-27-GBOctapharma Pharmazeutika Produktionsges.m.b.H, Oberlaaer Strasse 235, A-1100 Vienna, Austria40

A randomised, cross-over study to compare quality of life and satisfaction in primary immunodeficient patients treated with subcutaneous injections of Gammanorm® 165 mg/mL administered with two different delivery devices: injections using pump or rapid pushMedDRA - Primary immunodeficiency syndrome -10064859

DRKS00008784Octapharma Pharmazeutika Prod.Ges.m.b.H. | Octapharma Pharmazeutika Prod.Ges.m.b.H | A-1100 Vienna Austria |30

进行中（未招募）

A randomised, cross-over study to compare quality of life and satisfaction in primary immunodeficient patients treated with subcutaneous injections of Gammanorm® 165 mg/mL administered with two different delivery devices: injections using an infusion pump or syringeimmunodeficiency syndromeMedDRA version: 19.1Level: HLTClassification code 10036700Term: Primary immunodeficiency syndromesSystem Organ Class: 100000004870

EUCTR2014-003746-27-DEOctapharma Pharmazeutika Produktionsges.m.b.H, Oberlaaer Strasse 235, A-1100 Vienna, Austria40